Asia Pacific Prostate Cancer Nuclear Medicine Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (PET and SPECT), PET Product (F-18, C-11, and Ga68-PSMA), and End User (Hospitals, Clinics, and Others)

No. of Pages: 120    |    Report Code: BMIRE00025670    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Asia Pacific Prostate Cancer Nuclear Medicine Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Asia Pacific Prostate Cancer Nuclear Medicine Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Asia Pacific Prostate Cancer Nuclear Medicine Market – Key Market Dynamics

5.1 Growth Drivers
5.2 Market Opportunities
5.3 Future Trends
5.4 Impact of Drivers and Restraints

6. Asia Pacific Prostate Cancer Nuclear Medicine Market Regional Analysis

6.1 Asia Pacific Prostate Cancer Nuclear Medicine Market Overview
6.2 Asia Pacific Prostate Cancer Nuclear Medicine Market Revenue 2020-2028 (US$ Million)
6.3 Asia Pacific Prostate Cancer Nuclear Medicine Market Forecast Analysis

7. Asia Pacific Prostate Cancer Nuclear Medicine Market Analysis – by Type

7.1 PET
  • 7.1.1 Overview
  • 7.1.2 PET: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2031 (US$ Million)
7.2 SPECT
  • 7.2.1 Overview
  • 7.2.2 SPECT: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Prostate Cancer Nuclear Medicine Market Analysis – by PET Product

8.1 F-18
  • 8.1.1 Overview
  • 8.1.2 F-18: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
8.2 C-11
  • 8.2.1 Overview
  • 8.2.2 C-11: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Ga68-PSMA
  • 8.3.1 Overview
  • 8.3.2 Ga68-PSMA: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)

9. Asia Pacific Prostate Cancer Nuclear Medicine Market Analysis – by End User

9.1 Hospitals
  • 9.1.1 Overview
  • 9.1.2 Ga68-PSMA: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Clinics
  • 9.2.1 Overview
  • 9.2.2 Ga68-PSMA: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)

10. Asia Pacific Prostate Cancer Nuclear Medicine Market – Asia-Pacific Analysis

10.1 Asia-Pacific
  • 10.1.1 Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 10.1.1.1 Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 China: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 China: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by Type
    • 10.1.1.1.2 China: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
    • 10.1.1.1.3 China: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by End User
  • 10.1.1.2 India: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 India: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by Type
    • 10.1.1.2.2 India: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
    • 10.1.1.2.3 India: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by End User
  • 10.1.1.3 Japan: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Japan: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by Type
    • 10.1.1.3.2 Japan: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
    • 10.1.1.3.3 Japan: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by End User
  • 10.1.1.4 Australia: Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.4.1 Australia: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by Type
    • 10.1.1.4.2 Australia: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
    • 10.1.1.4.3 Australia: Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by End User
  • 10.1.1.5 Rest of Asia-Pacific : Asia Pacific Prostate Cancer Nuclear Medicine Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.5.1 Rest of Asia-Pacific : Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by Type
    • 10.1.1.5.2 Rest of Asia-Pacific : Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by PET Product
    • 10.1.1.5.3 Rest of Asia-Pacific : Asia Pacific Prostate Cancer Nuclear Medicine Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Asia Pacific Prostate Cancer Nuclear Medicine Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 ImaginAb
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Curium
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Jubilant Radiopharma
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 ABX advanced biochemical compounds GmbH
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Telix Pharmaceuticals Ltd
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Novartis AG
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Lantheus Medical Imaging, Inc.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - A Market

  1. ImaginAb
  2. Curium
  3. Jubilant Radiopharma
  4. ABX advanced biochemical compounds GmbH
  5. Telix Pharmaceuticals Ltd
  6. Novartis AG
  7. Lantheus Medical Imaging, Inc.
asia-pacific-prostate-cancer-nuclear-medicine-market